WO2003104401A3 - Gene lie au cancer cible en chimiotherapie - Google Patents

Gene lie au cancer cible en chimiotherapie Download PDF

Info

Publication number
WO2003104401A3
WO2003104401A3 PCT/US2003/017722 US0317722W WO03104401A3 WO 2003104401 A3 WO2003104401 A3 WO 2003104401A3 US 0317722 W US0317722 W US 0317722W WO 03104401 A3 WO03104401 A3 WO 03104401A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
target
disclosed
chemotherapy
linked gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/017722
Other languages
English (en)
Other versions
WO2003104401A2 (fr
Inventor
Reinhard Ebner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Data Inc
Original Assignee
Avalon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals Inc filed Critical Avalon Pharmaceuticals Inc
Priority to AU2003238897A priority Critical patent/AU2003238897A1/en
Publication of WO2003104401A2 publication Critical patent/WO2003104401A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003104401A3 publication Critical patent/WO2003104401A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des séquences géniques liées au cancer, et des séquences d'acides aminés dérivées, ainsi que des méthodes de dosage d'agents antitumoraux potentiels en fonction de leur modulation de l'expression desdits gènes liés au cancer. L'invention concerne également des anticorps destinés à réagir avec les polypeptides de l'invention, ainsi que des méthodes d'utilisation des anticorps dans le traitement d'états cancéreux, par exemple par utilisation de l'anticorps pour cibler les cellules cancéreusesin vivo afin de leur administrer des agents thérapeutiques. L'invention concerne enfin des méthodes de diagnostic dans lesquelles sont utilisées les séquences géniques.
PCT/US2003/017722 2002-06-05 2003-06-04 Gene lie au cancer cible en chimiotherapie Ceased WO2003104401A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003238897A AU2003238897A1 (en) 2002-06-05 2003-06-04 Cancer-linked gene as target for chemotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38609302P 2002-06-05 2002-06-05
US60/386,093 2002-06-05

Publications (2)

Publication Number Publication Date
WO2003104401A2 WO2003104401A2 (fr) 2003-12-18
WO2003104401A3 true WO2003104401A3 (fr) 2006-04-20

Family

ID=29736133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017722 Ceased WO2003104401A2 (fr) 2002-06-05 2003-06-04 Gene lie au cancer cible en chimiotherapie

Country Status (2)

Country Link
AU (1) AU2003238897A1 (fr)
WO (1) WO2003104401A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2517555A4 (fr) 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd Procédé de recherche et de dépistage d'une cible d'agent anticancéreux à l'aide d'un modèle animal non humain dans lequel a été transplantée une lignée de cellules cancéreuses établie sur nog
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
EP2749641B1 (fr) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Séparation de cellules souches cancéreuses
EP2772268B8 (fr) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Molécule spécifique des cellules souches cancéreuses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLARKE D.A. ET AL: "Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone", ONCOGENE, vol. 19, no. 36, 24 August 2000 (2000-08-24), pages 4125 - 4133, XP001094984 *
JUNG C.P. ET AL: "Flavopiridol Increases Sensitization to Gemcitabine in Human Gastrointestinal Cancer Cell Lines and Correlates with Down-Regulation of Ribonucleotide Reductase M2 Subunit", CLINICAL CANCER RESEARCH, vol. 7, no. 8, August 2001 (2001-08-01), pages 2527 - 2536, XP001179559 *
OLIE R.A. ET AL: "A Novel Antisense Oligonucleotide Targeting Survivin Expression Induces Apoptosis and Sensitizes Lung Cancer Cells to Chemotherapy", CANCER RESEARCH, vol. 60, no. 11, 1 June 2000 (2000-06-01), pages 2805 - 2809, XP002210584 *
WEBB C.P. ET AL: "The Geldanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network", CANCER RESEARCH, vol. 60, no. 2, 15 January 2000 (2000-01-15), pages 342 - 349, XP002996129 *

Also Published As

Publication number Publication date
WO2003104401A2 (fr) 2003-12-18
AU2003238897A1 (en) 2003-12-22
AU2003238897A8 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
WO2003097803A3 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
WO2003101400A3 (fr) Gene lie au cancer comme cible de chimiotherapie
WO2003105758A3 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
WO2008020596A3 (fr) Traitement ou prévention de cancers surexprimant le reg4 ou le kiaa0101
MX2022007575A (es) Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
WO2005100998A3 (fr) Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer
WO2007113648A3 (fr) Polythérapie à base d'un anticorps anti-ctla4
WO2005077091A3 (fr) Compositions de nicotinamide riboside kinase et procedes d'utilisation
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
AU9016998A (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
PL335334A1 (en) Combined treatment involing suppressor gene tumour therapy and chemotherapy for use in antineoplastic therapy
Sha et al. An electrochemical biosensor based on mild reduction-activated CRISPR/Cas12a system for sensitive detection of circulating tumor cells
WO2006116322A3 (fr) Compositions de nicotinamide riboside kinase et leurs methodes d'utilisation
WO2004031231A3 (fr) Genes et polypeptides lies au cancer de la prostate
WO2004078215A3 (fr) Utilisation d'enzymes specifiquement mises au point pour renforcer l'efficacite de promedicaments
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2003076579A3 (fr) Gene associe au cancer utilise en tant que cible pour la chimiotherapie
WO2003104401A3 (fr) Gene lie au cancer cible en chimiotherapie
WO2003097802A3 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
WO2004026238A3 (fr) Compositions immunotherapeutiques et methodes permettant de traiter des cancers moderement a bien differencies
WO2003104438A3 (fr) Genes lies au cancer servant de cibles de chimiotherapie
WO2002031198A3 (fr) Genes lies au cancer utilises comme cibles pour la chimiotherapie
WO2005062788A3 (fr) Proteines specifiques de la prostate exprimees dans le cancer et methodes d'utilisation associees
WO2003105783A3 (fr) Gene associe au cancer servant de cible pour la chimiotherapie
WO2004058167A3 (fr) Proteine specifique du sein exprimee dans le cancer, et ses methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP